BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35468260)

  • 21. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM; Shulman ST
    J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.
    Zhu BH; Lv HT; Sun L; Zhang JM; Cao L; Jia HL; Yan WH; Shen YP
    Eur J Pediatr; 2012 Mar; 171(3):571-8. PubMed ID: 22057683
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Delayed Development of Coronary Artery Aneurysm in Patients with Kawasaki Disease Who Were Clinically Responsive to Immunoglobulin.
    Matsuoka R; Furuno K; Nanishi E; Onoyama S; Nagata H; Yamamura K; Sugitani Y; Kuraoka A; Mizuno Y; Sagawa K; Honjo S; Hara T; Ohga S
    J Pediatr; 2020 Dec; 227():224-230.e3. PubMed ID: 32810506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S; Liu FF; Mammadov G; Wang JJ; Liu HH; Wu YF; Luo HH; Wu Y; Chen WX; Zhang DD; Wei W; Hu P
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):53. PubMed ID: 31366406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
    Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
    Kobayashi T; Inoue Y; Otani T; Morikawa A; Kobayashi T; Takeuchi K; Saji T; Sonobe T; Ogawa S; Miura M; Arakawa H
    Pediatr Infect Dis J; 2009 Jun; 28(6):498-502. PubMed ID: 19504733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of coronary artery abnormalities and variability of Z-score calculation in the acute episode of Kawasaki disease-A retrospective study from China.
    Liu HH; Qiu Z; Fan GZ; Jiang Q; Li RX; Chen WX; Liu FF; Wu Y; Wang JJ; Wu YF; Luo HH; Zhang DD; Hu P
    Eur J Clin Invest; 2021 Mar; 51(3):e13409. PubMed ID: 32916764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
    Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
    Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in the treatment of Kawasaki disease.
    Weng KP; Ou SF; Lin CC; Hsieh KS
    J Chin Med Assoc; 2011 Nov; 74(11):481-4. PubMed ID: 22100015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness.
    Yang TJ; Lin MT; Lu CY; Chen JM; Lee PI; Huang LM; Wu MH; Chang LY
    J Microbiol Immunol Infect; 2018 Jun; 51(3):321-331. PubMed ID: 28927685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.
    Uehara R; Belay ED; Maddox RA; Holman RC; Nakamura Y; Yashiro M; Oki I; Ogino H; Schonberger LB; Yanagawa H
    Pediatr Infect Dis J; 2008 Feb; 27(2):155-60. PubMed ID: 18174868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
    Kobayashi T; Kobayashi T; Morikawa A; Ikeda K; Seki M; Shimoyama S; Ishii Y; Suzuki T; Nakajima K; Sakamoto N; Arakawa H
    J Pediatr; 2013 Aug; 163(2):521-6. PubMed ID: 23485027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Kawasaki disease using locally product intravenous immunoglobulin.
    Sangtawesin C; Kirawitaya T; Layangkool T; Nawasiri W; Vimolsarawong N
    J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S656-60. PubMed ID: 14700163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kawasaki disease: part II. Complications and treatment.
    Bayers S; Shulman ST; Paller AS
    J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM; Özdemir R; Meşe T; Küçük M; Öner T; Devrim İ; Bayram N; Güven B; Tavlı V
    Turk J Pediatr; 2019; 61(5):648-656. PubMed ID: 32104995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood routine risk factors for coronary artery aneurysm in infants younger than 8 months with Kawasaki disease.
    Haiyan G; Jianming L; Suqian T; Dong Q; Shuang L; Jin Z
    BMC Pediatr; 2022 Jan; 22(1):29. PubMed ID: 34996405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Risk of Recrudescent Fever in Children With Kawasaki Disease Treated With Intravenous Immunoglobulin and Low-Dose vs High-Dose Aspirin.
    Platt B; Belarski E; Manaloor J; Ofner S; Carroll AE; John CC; Wood JB
    JAMA Netw Open; 2020 Jan; 3(1):e1918565. PubMed ID: 31899532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
    Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low- versus high-concentration intravenous immunoglobulin for children with Kawasaki disease in the acute phase.
    Suzuki T; Michihata N; Yoshikawa T; Saito K; Matsui H; Fushimi K; Yasunaga H
    Int J Rheum Dis; 2022 May; 25(5):576-583. PubMed ID: 35258165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.